| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CLN Stock Overview
Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations.
Celon Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł13.00 |
| 52 Week High | zł39.05 |
| 52 Week Low | zł12.68 |
| Beta | 0.79 |
| 1 Month Change | -12.99% |
| 3 Month Change | -16.45% |
| 1 Year Change | -65.33% |
| 3 Year Change | -69.30% |
| 5 Year Change | -61.54% |
| Change since IPO | -41.65% |
Recent News & Updates
We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Shareholder Returns
| CLN | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | -4.6% | 0.8% | -7.9% |
| 1Y | -65.3% | -1.8% | -35.7% |
Return vs Industry: CLN underperformed the Polish Pharmaceuticals industry which returned -0.4% over the past year.
Return vs Market: CLN underperformed the Polish Market which returned -33.1% over the past year.
Price Volatility
| CLN volatility | |
|---|---|
| CLN Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in PL Market | 11.7% |
| 10% least volatile stocks in PL Market | 3.8% |
Stable Share Price: CLN is more volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CLN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 504 | Maciej Wieczorek | https://www.celonpharma.com |
Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations. The company operates through Generic Drug and Innovative segments. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders.
Celon Pharma S.A. Fundamentals Summary
| CLN fundamental statistics | |
|---|---|
| Market Cap | zł663.39m |
| Earnings (TTM) | -zł17.40m |
| Revenue (TTM) | zł191.12m |
3.5x
P/S Ratio-38.1x
P/E RatioIs CLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLN income statement (TTM) | |
|---|---|
| Revenue | zł191.12m |
| Cost of Revenue | zł59.51m |
| Gross Profit | zł131.61m |
| Other Expenses | zł149.02m |
| Earnings | -zł17.40m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Nov 23, 2022
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 68.86% |
| Net Profit Margin | -9.11% |
| Debt/Equity Ratio | 0% |
How did CLN perform over the long term?
See historical performance and comparison